Company
Acadia Pharms INC
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
4
4 still marketed
Novel approvals
2
Approvals since 2021
8
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Nuplazid new use Priority reviewApr 27, 2026
- Nuplazid new use Priority reviewApr 27, 2026
- Daybue new use Priority reviewOrphanMar 27, 2026
- Daybue Stix approved OrphanDec 11, 2025
- Daybue new use OrphanSep 30, 2024
- Nuplazid new use Sep 15, 2023
- Nuplazid new use Sep 15, 2023
- Daybue approved NovelPriority reviewOrphanMar 10, 2023
- Nuplazid new use Jun 28, 2018
- Nuplazid approved Jun 28, 2018
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (4)
Newest FDA action first.
- Daybue Stix Trofinetide · 2025
- Nuplazid Pimavanserin Tartrate · 2016
- Nuplazid Pimavanserin Tartrate · 2018
- Daybue Trofinetide · 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.